Rivus Pharmaceuticals, Inc.
Charlottesville, US · Founded 2019 · Delaware corporation · 33 employees on LinkedIn · 4 known investors
Rivus Pharmaceuticals develops mitochondrial-targeted therapies to treat cardiometabolic diseases. The company's pipeline focuses on novel small-molecule and biologic drugs addressing metabolic dysfunction and cardiovascular health.
Founders & leadership
Rivus Pharmaceuticals, Inc. was founded in 2019 by Francisco Portell.
FP
Francisco PortellCo-founder & Vice President, Pharmaceutical Development
AC
Allen CunninghaminCo-founder & Chief Operating Officer
NH
Nancy HargreavesExecutive
JD
Jayson DallasinChief Executive Officer & President2023–2025
SK
Shaharyar KhaninCo-founder & Chief Scientific Officer
Board
FD
DD
PE
Patrick EnrightBoard director
IS
Ian SmithBoard director
RW
Rick WinninghamBoard director
Investors · 4
Medicxi✓ verifiedLondonvia Francesco De Rubertis · board
Longitude Capitalreported · 2 sourcesMenlo Park · $10M – $30M
RA CapitalreportedBostonvia Derek DiRocco · board
Also in the syndicate · 1
RxCapital
Funding
SEC filings, press & company announcements$223.5M disclosed across 4 of 5 rounds · 2019–2025
- Undisclosed amountSeries AJul 2021
Longitude Capital (lead), Medicxi (lead), RxCapital
Source ↗
▶$57MraisedJan 2025 · 7 investors · PharmaceuticalsRule 506(b)
▶$57MraisedJan 2025 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert SchottExecutive Officer
- Shaharyar KhanExecutive Officer, Director
- Rick WinninghamDirector
- Allen CunninghamExecutive Officer, Director
- Jayson DallasExecutive Officer, Director
- Tom O'NeilExecutive Officer
- Derek DiRoccoDirector
- Ian SmithDirector
- Erin LavelleDirector
- Francesco De RubertisDirector
- Offering amount
- $57M
- Amount sold
- $57M
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$66MraisedSep 2024 · 7 investors · PharmaceuticalsRule 506(b)
▶$66MraisedSep 2024 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ian SmithDirector
- Allen CunninghamExecutive Officer, Director
- Francesco De RubertisDirector
- Derek DiRoccoDirector
- Rick WinninghamDirector
- Shaharyar KhanExecutive Officer, Director
- Jayson DallasExecutive Officer, Director
- Nancy HargreavesExecutive Officer
- Offering amount
- $66M
- Amount sold
- $66M
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$66MraisedSep 2024 · 7 investors · PharmaceuticalsRule 506(b)
▶$66MraisedSep 2024 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ian SmithDirector
- Allen CunninghamExecutive Officer, Director
- Francesco De RubertisDirector
- Rick WinninghamDirector
- Nancy HargreavesExecutive Officer
- Jayson DallasExecutive Officer, Director
- Derek DiRoccoDirector
- Shaharyar KhanExecutive Officer, Director
- Offering amount
- $66M
- Amount sold
- $66M
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$34.5MraisedOct 2021 · 4 investors · PharmaceuticalsRule 506(b)
▶$34.5MraisedOct 2021 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Shaharyar KhanExecutive Officer, Director
- Patrick EnrightDirector
- Jayson DallasDirector
- Allen CunninghamExecutive Officer, Director
- Francesco De RubertisDirector
- Offering amount
- $35M
- Amount sold
- $34.5M
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapVivus18 shared keywordsVIVUS is a pharmaceutical company developing and commercializing therapies for patients with serious medical conditions and life-limiting diseases. The company advances innovative treatments through clinical development and commercialization expertise.
Corvuspharma16 shared keywordsCorvus Pharmaceuticals is a biopharmaceutical company developing immunology-focused medicines that target cellular components of the immune system, with therapeutic focus on immune diseases and cancer.
Robinhood13 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Companies competing with Rivus Pharmaceuticals, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Rivus Pharmaceuticals, Inc. do?
- Rivus Pharmaceuticals develops mitochondrial-targeted therapies to treat cardiometabolic diseases. The company's pipeline focuses on novel small-molecule and biologic drugs addressing metabolic dysfunction and cardiovascular health.
- Who founded Rivus Pharmaceuticals, Inc.?
- Rivus Pharmaceuticals, Inc. was founded by Francisco Portell in 2019.
- Who are Rivus Pharmaceuticals, Inc.'s investors?
- Rivus Pharmaceuticals, Inc.'s investors include Medicxi, Longitude Capital, RA Capital.
- How much funding has Rivus Pharmaceuticals, Inc. raised?
- Rivus Pharmaceuticals, Inc. has disclosed $223.5M raised across 4 of its 5 known rounds.
- Where is Rivus Pharmaceuticals, Inc. headquartered?
- Rivus Pharmaceuticals, Inc. is headquartered in Charlottesville, US.